---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028815"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2026-06-16T12:10:17+00:00"
generated_at: "2026-06-16T12:15:09.496307+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042

## Summary
- USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.
- First company-owned US patent for lead ADHD asset; includes composition-of-matter and method-of-treatment claims.
- Cingulate holds additional patents in 30 European territories, Australia, Canada, Israel; applications pending in Hong Kong and South Korea.
- CTx-1301 is a once-daily trimodal tablet using Precision Timed Release platform; being developed under FDA 505(b)(2) pathway.

## SEC filing metadata
- accession: 0001493152-26-028815
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2026-06-16T12:10:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/0001493152-26-028815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315226028815/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028815
- JSON: https://secwatch.observer/filing/0001493152-26-028815.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.